MATTHEW ROSSI: Open Payments
NPI 1104515170 · NEW SMYRNA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,848 in 79 payments from 20 companies in 2025. Trend: 2023 $773 · 2024 $1,098 · 2025 $1,848
Food & beverage: $1,813Education: $35
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $254 |
| Pulmonx Corporation | 6 | $240 |
| Regeneron Healthcare Solutions, Inc. | 10 | $215 |
| AstraZeneca Pharmaceuticals LP | 9 | $209 |
| JAZZ PHARMACEUTICALS INC. | 6 | $131 |
| Grifols USA, LLC | 5 | $112 |
| ABBVIE INC. | 5 | $108 |
| Actelion Pharmaceuticals US, Inc. | 2 | $104 |
| GENZYME CORPORATION | 4 | $91 |
| Insmed, Inc. | 4 | $80 |
Products named: DUPIXENT, CHARTIS CATHETER, GLASSIA, XYWAV, HYQVIA, FASENRA, Prolastin-C Liquid, UPTRAVI.
Industry payments across FL — which companies pay providers there.
